Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
81%
Rituximab
71%
Acute Myeloid Leukemia
68%
Large-Cell Lymphoma
44%
Overall Survival
41%
Retrospective Study
40%
Prognostic Factor
40%
Hematology
36%
Myelodysplastic Syndrome
35%
B Cell
34%
Non-Hodgkin Lymphoma
32%
Leukemia
32%
Clinical Trial
30%
Leukemia Cell
30%
Disease
29%
Elderly Patient
28%
Febrile Neutropenia
26%
Progression Free Survival
25%
Chronic Myelogenous Leukemia
25%
Mantle Cell Lymphoma
24%
Neoplasm
24%
T Cell
24%
Arm
24%
Induction Chemotherapy
23%
Disease Free Survival
23%
B-Cell Lymphoma
22%
Methotrexate
22%
Human Herpesvirus 8
22%
Drug Megadose
22%
Bleeding
22%
T Lymphocyte Receptor
22%
Imaging of Bone
22%
Immunoglobulin Light Chain
22%
Heavy Chain
22%
Human Leukocyte Antigen
22%
Subgroup Analysis
22%
Asciminib
22%
Peripheral Neuropathy
18%
Cancer
18%
Survival Rate
17%
Imaging Technique
16%
Drug Resistance
16%
Central Nervous System
16%
Cytarabine
16%
Programmed Cell Death
15%
Bosutinib
15%
Vincristine
15%
Cyclophosphamide
15%
Doxorubicin
15%
Chemotherapy Regimens
14%
Chromosome Aberration
14%
Two-Photon Microscopy
14%
Lymphoma Cell
14%
Allogenic Bone Marrow Transplantation
13%
Immunoglobulin A
13%
Immunoglobulin
13%
Dasatinib
13%
Nilotinib
13%
Tyrosine-Kinase Inhibitor
13%
Hematologic Malignancy
13%
Symptom
13%
Factor Analysis
12%
Virus DNA
12%
Adverse Event
12%
Immunotherapy
12%
Clinical Significance
12%
Myeloid Leukemia
12%
Prednisolone
12%
Epstein Barr Virus
12%
Mantle Cell Lymphoma International Prognostic Index
12%
Multivariate Analysis
11%
Hazard Ratio
11%
Hepatitis B
11%
Hepatitis B Virus
11%
Leukemia Relapse
11%
Bortezomib
11%
Bone Marrow Transplantation
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Waldenström's Macroglobulinemia
11%
Dexamethasone
11%
Whole Body Radiation
11%
Monosomy 7
11%
Essential Thrombocythaemia
11%
Duodenum Ulcer
11%
Bone Marrow Microenvironment
11%
Hematopoietic Stem Cell
11%
Bloodstream Infection
11%
Fibroblast Growth Factor 2
11%
PI3K/AKT Pathway
11%
Immunocompromised Patient
11%
Primary Central Nervous System Lymphoma
11%
Disease Burden
11%
Nucleic Acid Amplification
11%
Symptomatic Treatment
11%
Acute Promyelocytic Leukemia
11%
Tooth Extraction
11%
Factor VII
11%
Multiphoton Microscopy
11%
Fluorouridine
11%
Tumor Lysis Syndrome
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Chemotherapy
73%
Nonhodgkin Lymphoma
69%
Diffuse Large B Cell Lymphoma
67%
Remission
64%
Acute Myeloid Leukemia
60%
Neoplasm
36%
Large Cell Lymphoma
33%
Etoposide
33%
Survival Rate
31%
Progression Free Survival
30%
Disease Free Survival
30%
Clinical Trial
30%
Overall Survival
29%
Doxorubicin
28%
Vincristine
28%
Disease
28%
Prednisolone
26%
Cyclophosphamide
25%
Leukemia
24%
Febrile Neutropenia
24%
Retrospective Study
24%
Acute Leukemia
23%
B Cell Lymphoma
23%
Mantle Cell Lymphoma
23%
Infection
22%
Tumor Lysis Syndrome
22%
Hodgkin Disease
22%
Myelodysplastic Syndrome
22%
Dexamethasone
22%
Granulocyte Colony Stimulating Factor
22%
Pharmacokinetics
22%
Chronic Myeloid Leukemia
22%
Asciminib
22%
Malignant Neoplasm
19%
Antiproliferative Activity
18%
Hematologic Malignancy
15%
Colorectal Cancer
15%
Bosutinib
15%
Adverse Event
15%
Chemotherapy Regimens
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Cytochrome C
14%
Nucleoside Diphosphate Kinase A
13%
Bleomycin
13%
Follicular Lymphoma
13%
Cytarabine
13%
Caspase
12%
Interleukin 6
12%
Combination Therapy
12%
Bleeding
11%
Vasculotropin
11%
Two-Photon Microscopy
11%
Bortezomib
11%
Piperacillin Plus Tazobactam
11%
Burkitt's Lymphoma
11%
Bloodstream Infection
11%
Nucleolysin TIA 1 Isoform P40
11%
Methotrexate
11%
Hospital Infection
11%
Circulating Tumor DNA
11%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Promyelocytic Leukemia
11%
Syndrome
11%
Micafungin
11%
Ruxolitinib
11%
Carboplatin
11%
Antifungal Therapy
11%
Biological Marker
11%
Vibrio vulnificus
11%
Human Herpesvirus 8
11%
Angiofollicular Lymph Node Hyperplasia
11%
Caffeic Acid
11%
Intrathecal
11%
Solanum Torvum
11%
Ravulizumab
11%
Paroxysmal Nocturnal Hemoglobinuria
11%
Janus Kinase
11%
Seminoma
11%
Multiple Myeloma
11%
Anthraquinone
11%
Immunocompromised Patient
11%
Ifosfamide
11%
Hemopoietic Growth Factor
11%
Brentuximab Vedotin
11%
Pembrolizumab
11%
Azacitidine
11%
Mycosis
11%
Imatinib
11%
Emetine
11%
Thrombocythemia
11%
Core Binding Factor Beta
11%
Community Acquired Infection
11%
Antiinflammatory Activity
11%
Lenalidomide
11%
Interleukin 1
11%
Zinc Finger and BTB Domain Containing Protein 16
11%
Retinoic Acid Receptor
11%
Promyelocytic Leukemia Protein
11%
Protein Tyrosine Kinase Inhibitor
11%
Keyphrases
Acute Myeloid Leukemia
40%
Myelodysplastic Syndrome
24%
Leukemia Cells
23%
Intravascular Large B-cell Lymphoma (IVLBCL)
22%
Hematology
22%
Lymphoma Patients
21%
Unselected Patients
16%
Induction Chemotherapy
16%
Confidence Interval
15%
Treatment Results
14%
Lymphoma
14%
Non-Hodgkin Lymphoma
13%
Induction Therapy
13%
Extranodal
12%
Disease-free Survival
12%
D-index
12%
Diffuse Large B-cell Lymphoma (DLBCL)
12%
Central Nervous System Recurrence
11%
Complete Remission
11%
Retrospective Analysis
11%
Japan Clinical Oncology Group
11%
Rituximab-containing Chemotherapy
11%
Aggressive non-Hodgkin Lymphoma
11%
Secondary Leukemia
11%
Flow Cytometric
11%
Proliferative Effect
11%
Rolling Adhesion
11%
Dynamic Analysis
11%
Diagnostic Specimen
11%
Virus Pneumonia
11%
ILC2
11%
Monosomy 7
11%
DNA Detection
11%
Natural Killer T-cell Lymphoma
11%
Hematopoietic Function
11%
Vascular Endothelial Growth Factor
11%
Differentiation Syndrome
11%
COVID-19 mRNA Vaccination
11%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
11%
Oncogenetics
11%
Constant Region
11%
Font
11%
Rituximab Maintenance
11%
Indolent Lymphoma
11%
Tumor Lysis Syndrome
11%
Third Harmonic Generation
11%
Nonlinear Optics
11%
Near-infrared Excitation
11%
Real-time Quantitative
11%
Bystander Cells
11%
High Tumor Burden
11%
Second Harmonic Generation
11%
International Journals
11%
Dose-adjusted EPOCH-R
11%
Recombinant Activated Factor VII (rFVIIa)
11%
CRLF2
11%
Ruxolitinib
11%
Dental Extraction
11%
Febrile Neutropenia
11%
Interleukin-6
11%
Group Studies
11%
In Vitro Anticancer Activity
11%
Vibrio Vulnificus
11%
DNA Sources
11%
Cell-free DNA (cfDNA)
11%
Tumor DNA
11%
Flat Warts
11%
Solanum Torvum Swartz
11%
Multiphoton Excitation Microscopy
11%
Non-labeling
11%
Enhancer of Zeste Homolog 2 (EZH2)
11%
Methyl Caffeate
11%
H3K27me3
11%
Ravulizumab
11%
Hematological Diseases
11%
Liposomal Contrast Agent
11%
Upper Part
11%
ALK Expression
11%
Dendron
11%
NPM-ALK
11%
Magnetic Resonance Microimaging
11%
Cardiopulmonary Arrest
11%
Severe Infection
11%
Nanoparticle Distribution
11%
Macrophage Targeting
11%
Dexamethasone Palmitate
11%
Serum IgG Level
11%
R-CHOP Therapy
11%
System Restoration
11%
Gastroduodenitis
11%
Newly Diagnosed
11%
Successful Pregnancy
11%
Pure Red Cell Aplasia
11%
Deferasirox
11%
Cerebrospinal Fluid
11%
Plasma Epstein-Barr Virus DNA
11%
Epipharynx
11%
Combination Therapy
11%
Mitoxantrone
11%
Angioimmunoblastic
11%